SCLP.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 22:15):

Stats
今日成交量	762 868
平均成交量	395 545
市值	89.60M
EPS	£0 ( 2024-01-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-9.65
ATR14	£0.147 (1.52%)

Scancell Holdings PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Scancell Holdings PLC 财务报表

Annual	2022
营收:	£5.27M
毛利润:	£4.75M (90.04 %)
EPS:	£-0.0146

FY	2022
营收:	£5.27M
毛利润:	£4.75M (90.04 %)
EPS:	£-0.0146

FY	2022
营收:	£0
毛利润:	£0 (0.00 %)
EPS:	£-0.00250

FY	2021
营收:	£0.00
毛利润:	£0.00 (0.00 %)
EPS:	£-0.0392

Financial Reports:

No articles found.

Scancell Holdings PLC

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.